Condition: Schizophrenia · Sponsor: Neurocrine Biosciences
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.
This description comes directly from the study's public registry record.
Neurocrine Medical Information Call Center · 877-641-3461 · medinfo@neurocrine.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Key Inclusion Criteria: * Participant has a primary diagnosis of schizophrenia * Participant is experiencing an acute exacerbation or relapse of symptoms and currently warrants hospitalization. * Participants taking prohibited medications, including antipsychotics, must discontinue before study participation * Participant is willing and able to remain in an inpatient setting for the study duration, follow instructions, and comply with the protocol requirements Key Exclusion Criteria: * Participant has known hypersensitivity to any component of the formulation of NBI-1117568. * Participant has an unstable or poorly controlled medical condition or chronic disease * Participant is considered by the investigator to be at imminent risk of suicide or injury to self or others * Participant has a diagnosis of moderate or severe substance use disorder (with the exception of nicotine or caffeine dependence) within 6 months prior to screening * Participant has a positive alcohol test or drug screen for disallowed substances * Participants have a history of poor or suspected poor compliance in clinical research studies and/or in the investigator's opinion, the participant is not capable of adhering to the protocol requirements. Note: Other protocol-specified inclusion/exclusion criteria may apply.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Neurocrine Clinical Site | Bryant, Arkansas, United States | Recruiting |
| Neurocrine Clinical Site | Little Rock, Arkansas, United States | Recruiting |
| Neurocrine Clinical Site | Anaheim, California, United States | Recruiting |
| Neurocrine Clinical Site | Pico Rivera, California, United States | Recruiting |
| Neurocrine Clinical Site | San Diego, California, United States | Recruiting |
| Neurocrine Clinical Site | Sherman Oaks, California, United States | Recruiting |
| Neurocrine Clinical Site | Torrance, California, United States | Recruiting |
| Neurocrine Clinical Site | Hollywood, Florida, United States | Recruiting |
| Neurocrine Clinical Site | Miami Lakes, Florida, United States | Recruiting |
| Neurocrine Clinical Site | Atlanta, Georgia, United States | Recruiting |
| Neurocrine Clinical Site | Decatur, Georgia, United States | Recruiting |
| Neurocrine Clinical Site | Snellville, Georgia, United States | Recruiting |
+ 9 more locations — full list on the registry record.
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.